25th Annual Market Access Summit 2026 | Day 1

Gain insight into today’s sessions so you can get the most out of your conference experience.

Health Canada has responded to Stakeholder concerns about timely access by patients to life-saving therapies by launching initiatives designed to improve market access. Adapt your market access strategy to the latest advances in regulatory reductions.  Take back to your team ideas to help you: 

• Understand how the Red Tape Review launched on July 9, 2025 could positively impact your market access plans 
• Navigate an increasingly flexible clinical trial environment 
• Analyze how the first Ministerial Reliance Order provides new submission opportunities 

Develop a roadmap for aligning your 2027 clinical and regulatory strategy with Canada’s increasingly agile and patient-centric approval landscape. 

Value recognition is a critical factor in Canada’s ability to attract and sustain access to innovative medicines.  HTA agencies are fundamental to establishing value recognition by acting as system conveners and bringing together all stakeholders to create a foundational understanding of value that is incorporated into carried through the entire reimbursement process.  Take away actionable strategies to help you: 

• Explore how HTA frameworks are evolving to more fully and accurately capture the value of innovation, and examine what adaptations are needed to remain relevant, transparent, and impactful in a rapidly changing healthcare environment. 
• Examine how value recognition established through HTA is leveraged by payers and how the alignment between HTA assessments and provincial reimbursement decisions can be strengthened to support both timely patient access and system sustainability. 

Understand trends in value recognition and strengthen your submission for reimbursement – it has never mattered more. 

As innovative medicines increasingly launch in the United States years before reaching the Canadian market, stakeholders have a growing opportunity to leverage evidence generated outside Canada to address uncertainty in market access decision-making. Real-world experience can provide valuable insight into treatment patterns, persistence, adverse event management, medical resource utilization, and budget impact before reimbursement decisions are made. 

Explore how international evidence can help manufacturers reduce uncertainty for payers, and HTA organizations, strengthen decision-making, and support access planning. Gain practical insights to help you: 

• Understand how international experience can complement clinical and economic evidence 
• Evaluate how real-world utilization, medical resource use, and adverse event management can inform access decisions 
• Assess how evolving standards of care and competitive market dynamics influence reimbursement uncertainty 
• Determine where international evidence can strengthen payer engagement, budget impact assumptions, and launch planning 
• Explore how evidence generated prior to Canadian launch can support more informed access decisions 

Learn how international real-world experience can help reduce uncertainty, strengthen market access decision-making, and support sustainable access to innovation in Canada. 

Enhance your progress and impact delivered in the first phase of the 2023–2030 strategy. You’ll walk away with a blueprint to: 

• Bolster how global policy and geopolitical shifts are influencing strategic direction. 
• Leverage how to embed new forms of evidence in practice for HTA and access. 
• Ensure you understand how evidence expectations are evolving across payers, regulators, and industry. 
• Master what interested parties should anticipate from Canada’s Drug Agency through to 2030. 

Gain clarity on progress to date and how embedding new forms of evidence will redefine access and decision-making through 2030. 

Master the 2026 negotiation logic that requires an understanding of the pCPA processes. You’ll walk away with a blueprint to:

• Mastering Accelerated Negotiation Pathways: Understanding and navigating expedited negotiations processes.

• Optimizing Process Integration: Minimize operational friction and drive stronger negotiation alignment and collaboration.

Identify the tactical adjustments and evidence requirements necessary for manufacturers to achieve successful, predictable outcomes in an increasingly complex and scrutinized payer environment.

• Browse through different sponsor booths and source innovative market access expertise.
• Enter your name for a chance to win exciting prizes.
• Take advantage of event-specific offers and special content.

The CUSMA trade talks and the National Pharmacare program that is fragmented and seemingly stalled have introduced considerable uncertainty into the marketplace and the path forward.  Gain a better understanding of the impact on manufacturers and how private insurers may respond.  Take away ideas to: 

• Assess the impact this uncertainty has on allocating coverage of some medications between national pharmacare where it exists and private plans  
• Determine what impact Trump’s MFN call could have on manufacturer’s pricing decisions and the approach private insurers may take in response 
• How private payers can improve plan sustainability 
• Understand what drugs and therapies private payers will continue to cover and their listing criteria to enhance your submissions   

Expand your understanding of how ongoing funding is contingent on real-world clinical performance. Explore how RWE in lifecycle management involves navigating the shift toward HTA reassessments. You’ll walk away with practical tips to: 

• Understand how HTA agencies are thinking about generative AI 
• Analyze practical applications of generative AI across the RWE and market access lifecycle (e.g., evidence synthesis, protocol development, and supporting HTA and reimbursement planning) 
• Determine where AI can realistically add value today, as well as its current limitations 
• Develop governance, transparency, validation, and human oversight when using AI-generated outputs 
• Establish data quality and interoperability as foundational requirements for AI-enabled evidence generation 

Determine the strategic investments and multi-stakeholder partnerships required for you to transition from reactive data collection to a proactive, AI-enabled evidence strategy. 

• Experience the next level of market access innovation firsthand.
• Meet one-on-one with leading solution providers to discuss organizational hurdles.
• Brainstorm solutions and gain new perspectives and ideas.

U.S. Most-Favored-Nation (MFN) pricing proposals are creating uncertainty for pharmaceutical manufacturers, with potential implications beyond the U.S. The presentation will explore implications for established medicines and new launches, including launch timing, market availability, and commercial partnerships.  Take back to your team a blueprint to help you: 

• Assess key risks and signals Canadian stakeholders should monitor as international pricing policy evolves. 
• Understand the dynamics at play internationally that may influence access and launch decisions 
• Develop a strategy to navigate potential impact on pricing 

Identify the implications for your launch sequencing, price sustainability, and navigating increasing cross-market dependencies 

The challenge in Canada is rarely a lack of evidence: It’s that different decision-makers require different answers from the same evidence package. Most clinical and economic evidence is developed from a global perspective, while Canadian access decisions are made within a uniquely fragmented public and private payer environment. Take back to your team valuable insights you can use to help you: 

• Understand how the evolution of international policies and priorities will impact evidence requirements for Canada 
• Navigate the misalignments between global evidence strategies and local decision-making needs  
• Take advantage of as emerging opportunities to leverage new forms of evidence to better support market access strategies in Canada 

Translate global market access successes into actionable, local initiatives that expedite patient access and improve your portfolio viability in the Canadian market.  

Risk-sharing has moved from ambition to policy in Canada — yet whether these agreements deliver is decided after the signature: in the design, data, the monitoring and the reconciliation. Drawing on public value-based and rebate agreements with public and private payers around the world, this session cuts through the theory. Walk away with practical insights to:

• Evaluate which risk-sharing structures — financial and outcomes-based — are actually being signed
• Right-size the data infrastructure these agreements truly require, and work with the gaps in provincial health data
• Understand how payers define and mitigate “uncertainty” in practice, including for curative therapies
• Design for administrative feasibility, so monitoring, reconciliation and rebate recovery don’t become the reason agreements fail

Determine the core components of a value-based agreement that works for payers and manufacturers alike.

Review the key solutions and takeaways from today’s sessions. Source a summary of action points to implement in your work. Discuss tomorrow’s highlights!